Search Result

Results for "

anti-proliferation activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Acetyl-CoA Carboxylase (1) ADC Payload (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (3) Apoptosis (35) Aurora Kinase (1) Autophagy (5) Bacterial (3) Bcl-2 Family (6) Carbonic Anhydrase (1) Caspase (2) Cytochrome P450 (3) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Dopamine Receptor (6) Drug Derivative (3) Drug Intermediate (1) Drug Isomer (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) EGFR (2) Endogenous Metabolite (1) Epigenetic Reader Domain (3) ERK (2) Estrogen Receptor/ERR (3) FAK (1) Ferroptosis (1) FLT3 (2) Fungal (2) Glutaminase (1) GSK-3 (1) HDAC (2) Histone Demethylase (6) Histone Methyltransferase (4) HMG-CoA Reductase (HMGCR) (1) HSP (1) Influenza Virus (1) Integrin (1) Isocitrate Dehydrogenase (IDH) (1) JNK (2) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mitophagy (1) MMP (1) mTOR (1) NEDD8-activating Enzyme (1) Nuclear Hormone Receptor 4A/NR4A (1) Oxidative Phosphorylation (1) p38 MAPK (2) PARP (2) Peptide-Drug Conjugates (PDCs) (1) PROTACs (8) Proton Pump (1) PSMA (1) RAR/RXR (2) Ras (3) Reactive Oxygen Species (ROS) (3) Reference Standards (6) RET (1) Sirtuin (2) SOS1 (2) STAT (1) TAM Receptor (2) Topoisomerase (2) VEGFR (1) Wee1 (4) YAP (1) β-catenin (2)
By Research Areas:	Cancer (89) Cardiovascular Disease (7) Infection (4) Inflammation/Immunology (5) Metabolic Disease (6) Neurological Disease (9)

By Targets:

5-HT Receptor (3)

Acetyl-CoA Carboxylase (1)

ADC Payload (1)

AMPK (1)

Anaplastic lymphoma kinase (ALK) (2)

Antibiotic (3)

Apoptosis (35)

Aurora Kinase (1)

Autophagy (5)

Bacterial (3)

Bcl-2 Family (6)

Carbonic Anhydrase (1)

Caspase (2)

Cytochrome P450 (3)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (2)

Dopamine Receptor (6)

Drug Derivative (3)

Drug Intermediate (1)

Drug Isomer (1)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (1)

EGFR (2)

Endogenous Metabolite (1)

Epigenetic Reader Domain (3)

ERK (2)

Estrogen Receptor/ERR (3)

FAK (1)

Ferroptosis (1)

FLT3 (2)

Fungal (2)

Glutaminase (1)

GSK-3 (1)

HDAC (2)

Histone Demethylase (6)

Histone Methyltransferase (4)

HMG-CoA Reductase (HMGCR) (1)

HSP (1)

Influenza Virus (1)

Integrin (1)

Isocitrate Dehydrogenase (IDH) (1)

JNK (2)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Mitophagy (1)

MMP (1)

mTOR (1)

NEDD8-activating Enzyme (1)

Nuclear Hormone Receptor 4A/NR4A (1)

Oxidative Phosphorylation (1)

p38 MAPK (2)

PARP (2)

Peptide-Drug Conjugates (PDCs) (1)

PROTACs (8)

Proton Pump (1)

PSMA (1)

RAR/RXR (2)

Ras (3)

Reactive Oxygen Species (ROS) (3)

Reference Standards (6)

RET (1)

Sirtuin (2)

SOS1 (2)

STAT (1)

TAM Receptor (2)

Topoisomerase (2)

VEGFR (1)

Wee1 (4)

YAP (1)

β-catenin (2)

By Research Areas:

Cancer (89)

Cardiovascular Disease (7)

Infection (4)

Inflammation/Immunology (5)

Metabolic Disease (6)

Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12708

Chlorpromazine Maximum Cited Publications 128 Publications Verification	Dopamine Receptor Cytochrome P450 Autophagy 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT_2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNa_v1.7 channels (IC₅₀=25.9 μM; concentration-dependent) and HERG potassium channels (IC₅₀=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis .

HY-17502

Simvastatin 80+ Cited Publications MK 733	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Ferroptosis	Cardiovascular Disease Infection Cancer
Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a K_i of 0.2 nM.

HY-127103

FB23-2 25+ Cited Publications	Apoptosis	Cancer
FB23-2 is a potent and selective inhibitor of mRNA N ⁶-methyladenosine (m ⁶A) demethylase FTO, with an IC₅₀ of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .

HY-B0407A

Chlorpromazine hydrochloride Maximum Cited Publications 128 Publications Verification	Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT_2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNa_v1.7 channels (IC₅₀=25.9 μM; concentration-dependent) and HERG potassium channels (IC₅₀=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

HY-N0189

Aloe emodin 3 Publications Verification Rhabarberone; 3-Hydroxymethylchrysazine	mTOR Influenza Virus Apoptosis Autophagy	Cancer
Aloe emodin (Rhabarberone) is a natural hydroxyanthraquinone with antitumor activities. aloe-emodin can bind with mTORC2 and inhibit its kinase activity. Aloe emodin exerts antiproliferation effects and induces cellular apoptosis . Aloe emodin also exhibits antiviral activity that against influenza A virus .

HY-111431

p-Cresyl sulfate Maximum Cited Publications 6 Publications Verification p-Tolyl sulfate	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .

HY-109169

Bomedemstat 3 Publications Verification IMG-7289	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-B0735A

Fenoldopam mesylate 4 Publications Verification Fenoldopam methanesulfonate; SKF-82526 mesylate	Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam mesylate (SKF-82526) is a D₁ receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC₅₀=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-13313

XL888 5 Publications Verification	HSP Apoptosis	Cancer
XL888 is a potent and orally active HSP90 inhibitor with an IC₅₀ value of 24 nM. XL888 shows anti-proliferation activity and induces Apoptosis. XL888 shows anti-tumor activity .

HY-133618

Pomalidomide-C3-adavosertib	Wee1 PROTACs	Cancer
Pomalidomide-C3-adavosertib is a rapid and selective PROTAC Wee1 degrader (IC₅₀=3.58 nM). Pomalidomide-C3-adavosertib shows anti-cancer cell proliferation activity, and induces apoptosis .

HY-N0839

Quillaic acid 3 Publications Verification Quillaja sapogenin	Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Quillaic acid (Quillaja sapogenin)It is an anti-gastric cancer and anti-proliferation agent that can promote apoptosis of cancer cells. (apoptosis). Quillaic acidAlso has analgesic and local anti-inflammatory activity .

HY-B1360

Chlorquinaldol 5+ Cited Publications Chloquinan	Antibiotic Bacterial Fungal β-catenin Apoptosis	Infection Cancer
Chlorquinaldol (Chloquinan) is an antibacterial agent with the potential use in topical skin conditions and vaginal infections. Chlorquinaldol is a β-catenin/TCF4 inhibitor, showing anti-proliferation, anti-migration, and apoptosis-inducing activity in cancer cells .

HY-14507

YK-4-279 5+ Cited Publications	DNA/RNA Synthesis Apoptosis	Cancer
YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein). YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer .

HY-N10335

Harringtonolide 2 Publications Verification	FAK	Inflammation/Immunology Cancer
Harringtonolide is a potent RACK1 inhibitor (IC₅₀=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities .

HY-114323

PROTAC FLT-3 degrader 1	PROTACs FLT3 Apoptosis STAT MEK ERK	Cancer
PROTAC FLT-3 degrader 1 is an effective and selective FLT-3 PROTAC degrader with an IC₅₀ of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor. (Pink: FLT3 ligand (HY-168702); Black: Linker (HY-124380); Blue: VHL ligand (HY-125845)) .

HY-U00447

PK11000	MDM-2/p53 DNA Alkylator/Crosslinker	Cancer
PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities .

HY-109169A

Bomedemstat ditosylate 3 Publications Verification IMG-7289 ditosylate	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-146208

BRD4 Inhibitor-20 1 Publications Verification	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC₅₀ values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer .

HY-109169B

Bomedemstat hydrochloride 3 Publications Verification IMG-7289 hydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-164995

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .

HY-144627

PROTAC Axl Degrader 2	PROTACs TAM Receptor	Cancer
PROTAC Axl Degrader 2 is a potent and selective PROTAC Axl degrader with an IC₅₀ of 1.61 μM. PROTAC Axl Degrader 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 2 induces mehuosis .

HY-110329

ML179	Nuclear Hormone Receptor 4A/NR4A	Cancer
ML179 (SR-1309) is a inverse LRH1/NR5A2 (Liver receptor homologue-1) agonist with IC₅₀ of 320 nM. ML179 shows anti-proliferation activity in MDA-MB-231 cells. ML179 has the potential for the research of ER-negative breast cancer .

HY-169946

WEE1/PKMYT1-IN-1	Wee1	Cancer
WEE1/PKMYT1-IN-1 (compound 75) is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity .

HY-145737A

PROTAC SOS1 degrader-1 TFA	Ras PROTACs SOS1	Cancer
PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC₅₀ of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .

HY-150510

MS8511	Histone Methyltransferase	Neurological Disease Cancer
MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC₅₀ values of 100 nM (G9a) and 140 nM (GLP), and K_d values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .

HY-144624

PROTAC Axl Degrader 1	PROTACs TAM Receptor	Cancer
PROTAC Axl Degrader 1 is a potent and selective PROTAC Axl degrader with an IC₅₀ of 0.92 μM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces mehuosis .

HY-150401

Exatecan-amide-cyclopropanol	ADC Payload Topoisomerase	Cancer
Exatecan-amide-cyclopropanol (compound 1) is a anticancer agent. Exatecan-amide-cyclopropanol shows anti-proliferation activity against SK-BR-3 and U87 cells, with IC₅₀ values of 0.12 and 0.23 nM, respectively .

HY-161268

NAE-IN-1	Apoptosis NEDD8-activating Enzyme Reactive Oxygen Species (ROS)	Cancer
NAE-IN-1 (compound X-10) is a potent NAE1 inhibitor. NAE-IN-1 induces apoptosis and cell cycle arrest at the G2/M phase. NAE-IN-1 increases ROS levels and prevents cell migration. NAE-IN-1 shows anti-proliferation activity .

HY-109169C

Bomedemstat dihydrochloride 3 Publications Verification IMG-7289 dihydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) dihydrochloride is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat dihydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat dihydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-147932

ACC1/2-IN-2	Acetyl-CoA Carboxylase	Cancer
ACC1/2-IN-2 (compound PF-3) is a potent ACC1/2 inhibitor with IC₅₀ values of 22 and 48 nM for ACC1 and ACC2, respectively. ACC1/2-IN-2 has antiproliferation activity and can be used for cancer research .

HY-155993

YCH1899	PARP	Cancer
YCH1899 is an orally active PARP inhibitor, with an IC₅₀< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC₅₀ values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .

HY-150510A

MS8511 hydrochloride	Histone Methyltransferase	Neurological Disease Cancer
MS8511 (hydrochloride) is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC₅₀ values of 100 nM (G9a) and 140 nM (GLP), and K_d values of 44 nM (G9a) and 46 nM (GLP). MS8511 (hydrochloride) reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 (hydrochloride) can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .

HY-149726

EZH2-IN-17	Histone Methyltransferase	Cancer
EZH2-IN-17 (compound 28) is a potent and orally active EZH2 inhibitor with an IC₅₀ value of 0.95 nM. EZH2-IN-17 exhibits high anti-proliferation activity against different lymphoma cell lines including WSU-DLCL2, Pfeiffer and Karpas-422 (IC50 values of 2.36 nM, 1.73 nM, and 1.82 nM, respectively) .

HY-162837

AURKA against 1	Aurora Kinase	Cancer
AURKA against 1 is an inhibitor of AURKA (IC₅₀ less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3 .

HY-N3940

Gelsevirine	Others	Neurological Disease Cancer
Gelsevirine is the major alkaloid in Gelsemium elegans with potent anxiolytic effects. The anxiolytic mechanism of Gelsevirine may be involved in the agonist action of the glycine receptor in the brain. Gelsevirine has anti-proliferation activity with IC₅₀ values of 1.41 mM and 1.22 mM for SW480 cells and MGC80-3 cells, respectively .

HY-178106

SCN2	Drug Intermediate	Cancer
SCN2 is a esterase-responsive prodrug-based amphiphile composed of SN38 (HY-13704) and di-(triazole-[12]aneN3, N) moiety through a 7‑carbon alkyl chains. SCN2 has excellent self-assembly and reversible siRNA condensation capabilities as well as anti-proliferation activity against cancer cells. SCN2 can be used for synthesis of nanoparticles for drug delivery of lung cancer .

HY-155727

Sirt1/2-IN-2	Sirtuin Apoptosis	Cancer
Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC₅₀s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines .

HY-151434

GLS1 Inhibitor-6	Glutaminase Apoptosis	Cancer
GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC₅₀=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .

HY-145737

PROTAC SOS1 degrader-1	PROTACs SOS1 Ras	Cancer
PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC₅₀ of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .

HY-111431AR

p-Cresyl sulfate potassium (Standard) p-Tolyl sulfate potassium (Standard)	JNK p38 MAPK Reactive Oxygen Species (ROS) Reference Standards	Metabolic Disease
p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways .

HY-117376

(all-E)-UAB30 UAB30	RAR/RXR	Cancer
(all-E)-UAB30 (UAB30) is an retinoid X receptor (RXR) selective agonist.(all-E)-UAB30 shows anti-proliferation activity for MyLa, HuT 78, and HH cells with the IC₅₀ of 34.7, 5.1, and 22.4 μM respectively .

HY-142946

KRAS G12C inhibitor 44	Ras	Cancer
KRAS G12C inhibitor 44 (compound 54) is a potent and orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC₅₀s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo .

HY-171837

c9,t11,c15-CLNA	Caspase	Cancer
c9,t11,c15-CLNA is a conjugated linolenic acid (CLNA) isomer produced by Lactobacillus plantarum ZS2058. c9,t11,c15-CLNA has significant anti-proliferation activity against colon cancer cells (IC₅₀: 18.26 μM). c9,t11,c15-CLNA induces pyroptosis by activating the canonical pyroptosis pathway mediated by caspase-1. c9,t11,c15-CLNA can be used in the study of colon cancer .

HY-146095

p53 Activator 2	MDM-2/p53 DNA/RNA Synthesis Apoptosis	Cancer
p53 Activator 2 (compound 10ah) intercalats into DNA and results in significant DNA double-strand break.p53 Activator 2 increases the expression of p53, p-p53, CDK4, p21 to cause cell cycle arrest at G2/M phase.p53 Activator 2 induce apoptosis and significantly down-regulates the anti-apoptosis proteins Bcl-2, Bcl-xL and the levels of cyclin B1.p53 Activator 2 has anti-proliferation activity against MGC-803 cells, with an IC₅₀ of 1.73 µM. p53 Activator 2 displays potent anticancer efficiency against MGC-803 xenograft tumors models .

HY-169336

CQ-16	PARP PSMA	Cancer
CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC₅₀=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))

HY-B0407AR

Chlorpromazine hydrochloride (Standard)	Reference Standards Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

HY-154973

AMPK activator 11	Oxidative Phosphorylation Mitochondrial Metabolism AMPK	Metabolic Disease Cancer
AMPK activator 11 is an AMP-activated protein kinase (AMPK) activator with nanomolelevel antiproliferation activities against several CRCs. AMPK activator 11 selectively inhibits the RKO xenograft growth along by activating AMPK and upregulating oxidative phosphorylation (OXPHOS) ( mitochondrial metabolism ) and can be used for anti-tumor and metabolic disease research .

HY-151533

PBRM1-BD2-IN-6	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC₅₀ value of 0.22 μM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer .

HY-169946A

WEE1/PKMYT1-IN-2	Wee1	Cancer
WEE1/PKMYT1-IN-2 is the axial chiral P configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity .

HY-169946B

WEE1/PKMYT1-IN-3	Wee1	Cancer
WEE1/PKMYT1-IN-3 is the axial chiral M configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity .

Cat. No.	Product Name	Target	Research Area

HY-P10783

BGC0222	Peptide-Drug Conjugates (PDCs) Integrin	Cancer
BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to α_Vβ₃ with IC₅₀ values of 4.25 μM (α_Vβ₃) and 58.7 μM (α_Vβ₅). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks